Drug Trial Radar · NCT06740630
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,840
Planned (sponsor's estimate)
Start
Jan 10, 2025
Primary completion
Dec 25, 2026
Study completion May 17, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Dec 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months, up to 15 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the consistency of immune response to three different lots of GSK's investigational varicella vaccine (VNS Vaccine), and to compare the safety and immune response of VNS vaccine to an already approved varicella vaccine (VV) known as Varivax. The study will be conducted in healthy children aged 12 to 15 months, who have neither contracted varicella nor received a varicella vaccination.
Conditions
- Chickenpox
Interventions
Investigational varicella vaccine_Lot 1Biological
Investigational varicella vaccine of Lot 1 administered subcutaneously.
Investigational varicella vaccine_Lot 2Biological
Investigational varicella vaccine of Lot 2 administered subcutaneously.
Investigational varicella vaccine_Lot 3Biological
Investigational varicella vaccine of Lot 3 administered subcutaneously.
Marketed varicella vaccine_Lot 1Biological
Marketed varicella vaccine of Lot 1 administered subcutaneously.
Marketed varicella vaccine_Lot 2Biological
Marketed varicella vaccine of Lot 2 administered subcutaneously.
MMR vaccineBiological
MMR vaccine co-administered subcutaneously or intramuscularly.
Hepatitis A vaccineBiological
Hepatitis A vaccine co-administered intramuscularly.
PCV (pneumococcal conjugate vaccine) 13Biological
The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
PCV 20Biological
The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
VaxneuvanceBiological
The Vaxneuvance (15-valent pneumococcal conjugate vaccine) co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with seroresponse to Varicella Zoster Virus (VZV) anti-glycoprotein E (gE) Immunoglobulin (IgG) for the 3 lots of VNS vaccine groupsTime frame: At Day 43
- Geometric Mean Concentration (GMC) of anti-VZV gE IgG for the 3 lots of VNS vaccine groupsTime frame: At Day 43
- Percentage of participants with seroresponse to anti-VZV gE IgG for the 3 pooled lots of VNS vaccine groups compared with the 2 pooled lots of VV groupsTime frame: At Day 43
- GMCs of anti-VZV gE IgG for the 3 pooled lots of VNS vaccine groups compared with the 2 pooled lots of VV groupsTime frame: At Day 43
Locations
97 sites in 11 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Mobile, Alabama · Recruiting
GSK Investigational Site
Hot Springs, Arkansas · Recruiting
GSK Investigational Site
Sherwood, Arkansas · Recruiting
GSK Investigational Site
Canoga Park, California · Recruiting
GSK Investigational Site
Covina, California · Recruiting
GSK Investigational Site
Fullerton, California · Withdrawn
GSK Investigational Site
Long Beach, California · Withdrawn
GSK Investigational Site
Los Angeles, California · Recruiting
GSK Investigational Site
Paramount, California · Withdrawn
GSK Investigational Site
Sacramento, California · Recruiting
GSK Investigational Site
Ventura, California · Recruiting
GSK Investigational Site
Walnut Creek, California · Recruiting
GSK Investigational Site
Winnetka, California · Recruiting
GSK Investigational Site
Miami, Florida · Withdrawn
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Miami Lakes, Florida · Recruiting
GSK Investigational Site
Spring Hill, Florida · Recruiting
GSK Investigational Site
Tampa, Florida · Recruiting
GSK Investigational Site
Covington, Georgia · Recruiting
GSK Investigational Site
Ammon, Idaho · Recruiting
GSK Investigational Site
Moline, Illinois · Recruiting
GSK Investigational Site
South Bend, Indiana · Recruiting
GSK Investigational Site
Topeka, Kansas · Recruiting
GSK Investigational Site
Bardstown, Kentucky · Recruiting
GSK Investigational Site
Louisville, Kentucky · Recruiting
GSK Investigational Site
Haughton, Louisiana · Recruiting
GSK Investigational Site
Fall River, Massachusetts · Recruiting
GSK Investigational Site
Bingham Farms, Michigan · Recruiting
GSK Investigational Site
Jefferson City, Missouri · Recruiting
GSK Investigational Site
Lincoln, Nebraska · Recruiting
GSK Investigational Site
Lincoln, Nebraska · Withdrawn
GSK Investigational Site
Lincoln, Nebraska · Recruiting
GSK Investigational Site
The Bronx, New York · Recruiting
GSK Investigational Site
Charlotte, North Carolina · Recruiting
GSK Investigational Site
Monroe, North Carolina · Withdrawn
GSK Investigational Site
Cleveland, Ohio · Recruiting
GSK Investigational Site
Dayton, Ohio · Recruiting
GSK Investigational Site
Chickasha, Oklahoma · Recruiting
GSK Investigational Site
Tulsa, Oklahoma · Recruiting
GSK Investigational Site
Gresham, Oregon · Recruiting
Showing 40 of 97 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.